News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AmpliPhi Bio (APHB) To Hold 2017 Second Quarter And Business Update Conference Call On August 14



8/7/2017 6:28:45 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces that management will hold a business update conference call on Monday, August 14, 2017 beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

Live Call: U.S. 877-866-5534
International 346-406-0930
Passcode 53278337
Live Webcast:

AmpliPhi IR Website

The webcast replay will be available approximately 2 hours after completion of the call and will be archived for 30 days.

Replay: U.S. 855-859-2056
International 404-537-3406
Passcode 53278337

The replay will be available for 48 hours starting approximately 2 hours after completion of the call

About AmpliPhi Biosciences

AmpliPhi Biosciences Corporation is a biotechnology company pioneering the development and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. In May 2017, AmpliPhi announced a new strategic emphasis on developing precisely targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. AmpliPhi has reported results from two Phase 1 clinical trials of AB-SA01, one for the treatment of Staphylococcus aureus in chronic rhinosinusitis patients (safety and preliminary efficacy) and one to evaluate the safety of AB-SA01 when administered topically to the intact skin of healthy adults. AmpliPhi has additional bacteriophage-based preclinical products in development, including for the treatment of Pseudomonas aeruginosa infections. AmpliPhi has received positive feedback from the U.S. Food and Drug Administration (FDA) and UK Medicines and Healthcare products Regulatory Agency (MHRA) on its development plans.

At the Company:
AmpliPhi Biosciences
Matthew Dansey
(858) 800-4869
md@ampliphibio.com
or
Investor Relations:
LHA Investor Relations
Jody Cain
(310) 691-7100
jcain@lhai.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES